NFYA and cancer: In 2022, Fengyan Han et al. discovered that through inhibiting the nucleocytoplasmic transport of NFYA, the metastasis of colorectal cancer can be suppressed by using delanzomib, an antagonist of the NFYA-related signaling pathway, which further demonstrated the potential of NFYA-targeted chemotherapy for cancer [41].